Tenax therapeutics, inc. (TENX)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Oct'15Sep'15Jul'15Jun'15Mar'15Jan'15Oct'14Jul'14Jan'14Oct'13Jul'13Jan'13Oct'12Jul'12Apr'12Jan'12Oct'11Jul'11Jan'11Oct'10Jul'10
Product Revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

0

24

35

2

14

11

8

4

27

59

52

36

6

Cost of sales

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

0

3

27

1

9

5

3

2

10

34

25

8

1

Net product revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

0

21

7

1

5

5

5

2

16

24

26

27

5

Government grant revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-49

-

0

-

49

-

0

-

-

41

34

157

221

509

266

90

146

78

0

0

0

-

Total net revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

41

55

165

222

514

272

95

148

95

24

26

27

-

Operating expenses
General and administrative

-1,322

8,776

-1,343

-1,170

-1,179

9,587

-1,191

-1,577

-1,164

9,973

-1,056

-1,791

-1,447

6,989

-1,265

-1,239

1,761

581

1,230

1,425

1,368

1,934

1,618

1,907

1,586

1,449

1,783

1,421

982

1,441

422

1,262

1,207

1,422

1,660

1,800

2,282

1,511

1,883

Research and development

-1,342

5,520

-916

-649

-482

1,971

-362

-311

-58

7,055

-253

-1,222

-2,051

15,862

-3,234

-3,431

3,943

2,859

2,518

1,678

1,745

1,947

1,582

1,227

2,556

966

689

748

772

369

604

637

722

599

488

651

498

572

1,145

Restructuring expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2

170

47

0

0

0

0

-

-

-

Loss on impairment of long-lived assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,034

-

-

-

-

-

-

-

0

0

0

29

0

0

0

0

0

0

Loss on impairment of long-lived assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

-2,665

14,297

-2,260

-1,819

-1,661

11,559

-1,554

-1,888

-1,223

17,029

-1,310

-3,014

-3,498

56,117

-4,500

-4,671

5,705

2,405

3,749

3,103

3,114

4,916

3,200

3,134

4,143

2,416

2,473

2,169

1,755

1,813

1,197

1,947

1,959

2,022

2,149

2,452

2,781

2,083

3,028

Net operating loss

2,665

-14,297

2,260

1,819

1,661

-11,559

1,554

1,888

1,223

-17,029

1,310

3,014

3,498

-56,117

4,500

4,671

-5,705

-2,454

-3,749

-3,103

-3,114

-4,866

-3,200

-3,134

-4,143

-2,416

-2,431

-2,114

-1,589

-1,591

-682

-1,675

-1,864

-1,873

-2,054

-2,428

2,754

2,056

3,023

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0

0

0

1

1

1

0

0

46

69

1,416

655

821

867

1,925

762

5,341

871

435

-43

5

1

Loss on extinguishment of debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

Other income

-10

300

-36

-58

-44

149

-18

-21

-30

693

-76

-28

-223

678

-226

-30

343

54

225

183

81

120

263

267

88

291

-849

-0

0

0

-6

14

12

-82

-3

-5

-253

-10

-22

Net loss

2,654

-13,997

2,223

1,761

1,617

-18,740

1,535

1,867

1,192

-16,335

1,234

2,986

3,275

-47,477

4,273

4,641

-5,361

-2,399

-3,524

-2,920

-3,034

-4,747

-2,939

-2,868

-4,054

-2,171

-3,350

-3,531

-2,245

-2,412

-1,557

-3,586

-2,614

-7,298

-2,929

-2,869

2,544

2,051

3,002

Unrealized loss (gain) on marketable securities

1

0

0

-0

-1

-10

-6

-10

10

10

-3

-2

-6

68

39

-78

-140

100

-21

-12

65

67

-177

-95

-23

65

0

0

0

-

-

-

-

-

-

-

-

-

-

Total comprehensive loss

2,656

2,792

2,224

1,761

1,616

9,537

1,529

1,857

1,203

1,354

1,230

2,983

3,269

29,715

4,312

4,563

5,221

2,500

3,503

2,907

3,100

4,815

2,761

2,772

4,031

2,236

3,350

3,531

4,339

-

-

-

-

-

-

-

-

-

-

Net loss

2,654

-13,997

2,223

1,761

1,617

-18,740

1,535

1,867

1,192

-16,335

1,234

2,986

3,275

-47,477

4,273

4,641

-5,361

-2,399

-3,524

-2,920

-3,034

-4,747

-2,939

-2,868

-4,054

-2,171

-3,350

-3,531

-2,245

-2,412

-1,557

-3,586

-2,614

-7,298

-2,929

-2,869

2,544

2,051

3,002

Preferred stock dividend

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-1,095

-2,551

-2,094

0

0

0

-

-

-

-

-

-

-

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,868

-

-

-4,446

6,083

4,339

2,412

1,557

3,586

-

-

-

-

-

-

-

Net loss per share, basic and diluted

-0.38

-0.41

-0.33

-0.28

-0.33

-5.87

-1.05

-1.28

-0.84

-0.95

-0.87

-2.12

-2.33

-30.73

-0.15

-0.17

-0.19

-0.09

-0.13

-0.10

-0.11

-0.17

-0.10

-

-0.14

-0.08

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted average number of common shares outstanding, basic and diluted

6,974

6,768

6,741

6,385

4,887

1,920

1,462

1,453

1,422

1,411

1,411

1,411

1,406

-78,735

28,119

28,119

28,119

28,119

28,119

28,119

28,119

28,119

28,119

-

28,107

27,661

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss per share, basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.10

-

-

-0.43

-1.23

-2.06

-1.45

-0.97

-2.38

-11.62

-0.26

-0.12

-0.12

-0.11

-0.09

-0.13

Weighted average number of common shares outstanding, basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

28,119

-

-

10,260

4,942

2,102

1,658

1,603

1,509

-69,573

27,558

23,805

23,395

23,391

23,387

23,215

Net loss per share, diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.10

-

-

-0.44

-1.25

-3.36

-2.78

-2.63

-4.30

-13.06

-0.39

-0.29

-0.33

-0.11

-0.09

-0.13

Weighted average number of common shares outstanding, diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

28,119

-

-

10,266

4,948

2,210

1,767

1,712

1,618

-74,305

29,731

25,980

24,143

23,391

23,387

23,215